Gestational Trophoblastic Disease
A group of diseases arising from pregnancy that are commonly associated with hyperplasia of trophoblasts (TROPHOBLAST) and markedly elevated human CHORIONIC GONADOTROPIN. They include HYDATIDIFORM MOLE, invasive mole (HYDATIDIFORM MOLE, INVASIVE), placental-site trophoblastic tumor (TROPHOBLASTIC TUMOR, PLACENTAL SITE), and CHORIOCARCINOMA. These neoplasms have varying propensities for invasion and spread.
Subtype terms (1)
More specific conditions that are subtypes of Gestational Trophoblastic Disease in the MeSH hierarchy.
- Hydatidiform Mole
8 drugs (6 approved, 2 experimental)
Drugs by status
Approved for this indication (1)
Phase 3 trials (12)
Phase 2 trials (24)
Phase 1 trials (1)
Other trials (3)
Organizations
Organization Involved with Phase 3 Indications (15)
- National Cancer Institute (NCI)
- Huazhong University of Science and Technology
- Eastern Cooperative Oncology Group
- Gynecologic Oncology Group
- Mansoura University
- NRG Oncology
- Oregon Health and Science University
- Sichuan University
- University of the Philippines
- Assiut University
- University of California, San Diego
- Zhejiang University
- Shandong University
- Zhongshan Medical University
- Sun Yat-Sen University
Organization Involved with Phase 2 Indications (12)
- Merck KGaA
- Tracon Pharmaceuticals Inc.
- National Institutes of Health (NIH)
- Case Western Reserve University
- Cancer Treatment Centers of America
- University of Washington
- Southwest Oncology Group
- University of Toronto
- Cha Medical University
- University of Lyon
- Chinese Academy of Medical Sciences
- The University of Texas, Dallas
Organization Involved with Phase 1 Indications (2)
Organization Involved with Other Experimental Indications (3)